PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine
Authors
Keywords
-
Journal
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
Volume 118, Issue 4, Pages 429-432
Publisher
Wiley
Online
2011-01-18
DOI
10.1111/j.1471-0528.2010.02838.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of ADP Ribosylation Prevents and Cures Helicobacter-Induced Gastric Preneoplasia
- (2010) I. M. Toller et al. CANCER RESEARCH
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
- (2009) Yvette Drew et al. DRUG RESISTANCE UPDATES
- PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases
- (2009) Andreína Peralta-Leal et al. FREE RADICAL BIOLOGY AND MEDICINE
- PARP Inhibitors: Will the New Class of Drugs Match the Hype?
- (2009) Rabiya S. Tuma JNCI-Journal of the National Cancer Institute
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
- (2008) E. M. Swisher et al. CANCER RESEARCH
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search